What do systematic reviews say?

Intervention not reported

• Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults,… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 20 participants
  Very low

Rifapentine plus isoniazid weekly vs isoniazid

Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 0.44 [0.18, 1.07]
  1 study · 7731 participants
  Moderate

Rifapentine plus isoniazid weekly vs isoniazid

Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 1.19 [1.16, 1.22]
  1 study · 7731 participants
  Moderate

Rifapentine plus isoniazid weekly vs isoniazid

Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 1.32 [1.07, 1.64]
  1 study · 7731 participants
  Moderate

Rifapentine plus isoniazid weekly vs isoniazid

Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).

• Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative… 2013 · Cochrane Headline outcomes only
  RR 0.16 [0.1, 0.27]
  1 study · 7799 participants
  High